AUXL up +0.80% percent Today $AUXL High is at 33.16 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 1:28 PM

AUXL up +0.80% percent Today $AUXL High is at 33.16 and the Low 32.74 with current volume of 239,185.

Recent News posted below.

Auxilium Pharmaceuticals AUXL other info.
http://investorshangout.com/Auxilium-Pharmace...UXL-53427/

AUXL Auxilium Pharmaceuticals Recent Headline News

Waiting period over for Endo/Auxilium merger
Seeking Alpha - at Seeking Alpha - 1 hr 32 mins ago

ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)

Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals
PR Newswire - Wed Nov 19, 6:30AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"

in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on November 18, 2014. Endo now expects the deal to close in the first quarter of 2015, subject to pending customary closing conditions.
ENDP: 69.50 (-0.01), ENL.TO: 78.60 (-0.99), AUXL: 33.01 (+0.32)

Shares of AUXL Up 61.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 18, 9:09AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 61.43% as of today's recent price of $32.60.
AUXL: 33.01 (+0.32)

Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Business Wire - Tue Nov 18, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry.
AUXL: 33.01 (+0.32), ATRS: 2.23 (-0.03)

Auxilium Pharmaceuticals Earnings Review: 18 Days after Announcement Shares Up 0.9% (AUXL)
Comtex SmarTrend(R) - Mon Nov 17, 1:26PM CST
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.17, representing a gain of 0.9% since the company reported earnings 18 days ago.
AUXL: 33.01 (+0.32)

NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 33.01 (+0.32), NPSP: 31.42 (+0.74), AMGN: 162.63 (+0.39), BIOD: 1.58 (-0.03)

Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), RGLS: 16.72 (-1.40)

ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), ARQL: 1.26 (-0.02)

61.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 4:47PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 61.92% as of today's recent price of $32.70.
AUXL: 33.01 (+0.32)

Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 46.87 (+0.17), AVNR: 13.84 (+0.14), AUXL: 33.01 (+0.32), GSK: 46.29 (+0.01)

Intercept Pharmaceuticals' Shares Crash on FLINT Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:03PM CST
Shares of Intercept Pharmaceuticals, Inc. (ICPT) plunged 30.1% following the publication of additional results from the FLINT trial on its lead candidate, obeticholic acid (OCA) in The Lancet.
CYTK: 4.18 (+0.02), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), ICPT: 156.62 (-5.88)

Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 213.19 (-0.18), VRX: 141.85 (-0.09), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)

Auxilium Pharmaceuticals Earnings Hindsight: Up 2.7% in Last 11 Days (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 12:17PM CST
A week ago on October 30th, 2014 Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings and analysts, on average, expected earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.75, representing a gain of 2.7% since the company reported earnings 11 days ago.
AUXL: 33.01 (+0.32)

Nektar Therapeutics Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 11:20AM CST
Nektar (NKTR) reported third-quarter 2014 earnings of 53 cents per share, beating the Zacks Consensus Estimate of 39 cents.
BAX: 72.37 (-0.21), AUXL: 33.01 (+0.32), AZN: 75.34 (+1.36), NKTR: 13.93 (-0.16)

Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST

ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)

Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 213.19 (-0.18), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)

Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 6.47 (+0.09), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), BIOD: 1.58 (-0.03)

VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 33.01 (+0.32), VVUS: 3.11 (+0.07), AMAG: 35.51 (+0.17), SNY: 48.26 (-0.10)

Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 268.22 (-1.38), VRX: 141.85 (-0.09), IRWD: 13.55 (+0.15), AUXL: 33.01 (+0.32)

Auxilium Pharmaceuticals Inc. (AUXL) Stock Research Links

AUXL Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Business Leaders Push for Justice Reform Policy

Business stepping up to bat for justice reform? Yeah, that’s what's shaking over in Washington, D.C. this Constitution Day. We're seeing a gathering of senior business execs, policymakers, and public safety advocates, intent on driving judicial reform in the U.S. Usually, the suits in these rooms talk about profit margins and quarterly results, but this time they're...

Baystate Noble Plans Major ED Expansion for Future Needs

A Trusted Name in Healthcare Steps Up When a healthcare player like Baystate Health decides to jump into the deep end with an expansion project, you know they're not just doodling on napkins. With a legacy stretching back to 1883, Baystate Health, anchored deeply in western New England, isn't just expanding for fun—it's a move to cement its position as a crucial...

Jeen's Real-Time AI Cost Management Unveiled

Unmasking the Ghosts in AI Expenses Enterprises are thrashing around in the digital ocean of AI, yet many still can't see what's draining their coffers. It's not just the savant data scientists racking up the charges; it's every automated agent chipping away at resources—unnoticed until the bill finally lands. That's where Jeen is stepping in, flipping the script on...

Jamba's Cloud Whip: A Bold Blend in Beverage Scene

An Unexpected Shake-Up in the Beverage Game Folks, brace yourselves because Jamba's making some bold moves. I remember a time when a smoothie was just a smoothie, but now, they're stacking up a new deck with this fancy thing they're calling 'Cloud Whip'. It's basically a way to slap some extra protein onto your drink, with 10 grams coming at you like a freight train...

SCO at 25: China's Strategic Push for Regional Growth

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Innventure Faces Class Action Over Alleged Deception

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Kevin Hart & Pragmatic Play Revamp Live Casino Scene

Where Comedy Meets Chances You've got Kevin Hart, larger than life, and then you've got Pragmatic Play—a key player in iGaming. Put them together and you've got an event that might turn the usual casino lights into a full-blown spotlight. They're not just throwing dice, they're shaking up the market with potential way beyond what meets the eye. Okay, so here's the...

Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Comcast Unveils Game-Changing Next-Gen Video AI

Comcast Technology Solutions Takes a Big Swing Well, Comcast Technology Solutions (CTS) is stepping up to the plate with an offering that just might knock it out of the park for broadcasters and content creators. They're rolling out an ambitious suite of AI-powered video workflow tools that could potentially redefine how operators handle their media libraries. The buzz is...